Update on COVID-19

Background Image

As the COVID-19 pandemic continues to evolve, Norgine is fully committed to doing everything we can to manage this unprecedented situation and to support our staff, customers, patients and partners through this challenging period.

Our priority is to protect the health of our staff whilst ensuring that we can continue to supply medicines and products to our customers and ultimately to the 22 million patients we help every year.

Read more…

Bringing transformative medicines to patients for over a century




We are proud to be able to help 22 million patients worldwide every year.

Founded in 1906, Norgine is a leading European specialist pharmaceutical company with a strong global network of partnerships.

This enables us to acquire, develop and commercialise innovative products that make a real difference to the lives of patients around the world.


Identifying opportunities for patients.
Bringing them to market


Agile and adaptable infrastructure to work with partners

We partner in many different ways – licensing or acquisition and special purpose vehicle (SPV)


€419 million net product sales in 2019

Our positive performance in 2019 allows us to reinvest in medicines for the future


Multiple specialist therapy areas

Gastroenterology, hepatology, cancer and supportive care


One Norgine approach and infrastructure. Over 1,300 people

We believe that all of our employees contribute to our future success as a company

Collaborating with partners who share our vision for improving healthcare

Partner for a healthy life